期刊文献+

PI3K-Akt-mTOR信号传导通路与乳腺癌关系的研究进展 被引量:5

下载PDF
导出
摘要 乳腺癌发病机制复杂,涉及到多条信号通路如丝裂原活化蛋白激酶(Mitogen-activated protein kinase,MAPK)、磷酸肌醇3-激酶(Phosphati-dylinositol 3-kinase,PDK)/蛋白激酶B(PKB,protein kinaseB,Akt)信号通路等的调控。其中PI3K-Akt-mTOR通路成为近年来研究的热点,以此信号通路中的关键分子为靶点的乳腺癌治疗正在研究中。本文对近几年来有关乳腺癌中PI3K-Akt-mTOR信号通路突变和乳腺癌耐药机制的研究及乳腺癌分子靶向治疗等方面作一综述,并对乳腺癌中PI3K-Akt-mTOR信号通路机理研究的意义及新的靶向药物进行展望。
作者 吴群丹
出处 《海峡药学》 2020年第1期172-174,共3页 Strait Pharmaceutical Journal
  • 相关文献

参考文献3

二级参考文献105

  • 1Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene [ J ] . Science, 1987, 235: 177-182.
  • 2Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer [ J ] . Oncologist, 2004, 9: 606- 616.
  • 3Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase Ⅲ study of trastuzumab, paclitaxcl, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer [ J ] . J Clin Oncol, 2006, 24: 2786-2792.
  • 4Piccart-Gebhart M J, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J].N Engl J Med, 2005, 353: 1659-1672.
  • 5Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Rceceptor 2 testing in breast cancer [ J ] . J Clin Oncol, 2007, 25:118-145.
  • 6Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti- HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatie disease [J]. J Clin Oncol, 1999, 17: 2639-2648.
  • 7Delord JP, Allal C, Canal M, et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma [ J ] . Ann Oncol, 2005, 16: 1889-1897.
  • 8Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumah, and loss of PTEN predicts trastuzumah resistance in patients [J].Cancer Cell, 2004, 6: 117-127.
  • 9Lane HA, Motoyama AB, Benvink I, et al. Modulation of p27/ Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling [ J ] . Ann Oncol, 2001, 12 Snppl 1:S21-S22.
  • 10Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis [ J ] . Oncogene, 2000, 19: 3460-3469.

共引文献8

同被引文献62

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部